NASDAQ · PALI
Palisade Bio, Inc.
$1.19$0.00 (0.0%)
Palisade Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.39% below the high.
Loading market information…
NASDAQ · CLSD · USD
Stock price, earnings
Quote as of Mar 12, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Clearside Biomedical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.6% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Clearside Biomedical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials. Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $90.00K-28.85% vs estimate |
| Q1 2024 | May 9, 2024 | -$2.55-1,721.43% vs estimate | $230.00K-60.68% vs estimate |
|---|
| Q4 2023 | Mar 12, 2024 | -$1.20-1,233.33% vs estimate | $6.35M+43.12% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.19$0.00 (0.0%)
Palisade Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.39% below the high.
$5.19-$0.06 (-1.14%)
Cingulate Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.35% below the high.
$16.54+$0.80 (+5.08%)
Pelthos Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.89% below the high.
$0.89-$0.06 (-6.32%)
Allarity Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.63% below the high.
$2.85-$0.15 (-5.0%)
Entero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.2% below the high.
$1.01-$0.05 (-4.72%)
Lisata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.08% below the high.
$1.19+$0.05 (+4.39%)
MetaVia Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.99% below the high.
$3.77+$0.47 (+14.24%)
Lexaria Bioscience Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.55% below the high.
